The Volokh Conspiracy
Mostly law professors | Sometimes contrarian | Often libertarian | Always independent
Pharma Co. Seems Ready to Withdraw Request for Preliminary Injunction to Take Down Anesthesiology Journal Articles
The case is Pacira BioSciences v. American Society of Anesthesiologists, a trade libel lawsuit filed over journal articles and other publications questioning the efficacy of Pacira's pain-killer Exparel.
I blogged two weeks ago about the lawsuit, and the motion for preliminary injunction; I noted that preliminary injunctions in libel cases are generally seen as unconstitutional "prior restraints," even if a permanent injunction following a trial might be permissible. (I expressed no opinion on whether the plaintiff would indeed be able to prove trade libel at trial.)
Just this morning, Pacira's lawyers (from the megafirm Latham & Watkins) filed a letter suggesting that they're likely to withdraw the motion for preliminary injunction:
The parties agree on two important things: (1) that the parties are ready to address the merits of Pacira's trade libel claim and (2) to do so swiftly. The only difference in the parties' proposals is that Defendants request discovery and a preliminary injunction hearing now, while Pacira is seeking final resolution more efficiently. A preliminary injunction will not bring final resolution to the matter, so Defendants' proposal would presumably be followed by additional discovery and eventually a permanent injunction hearing.
Since both parties want this resolved as soon as possible, Pacira proposes to forego consideration of a preliminary injunction and move directly to determination of a permanent injunction, with expedited discovery and determination. Discovery and briefing on damages would follow a resolution of the issues relating to liability.
Sounds like a good move to me.
Editor's Note: We invite comments and request that they be civil and on-topic. We do not moderate or assume any responsibility for comments, which are owned by the readers who post them. Comments do not represent the views of Reason.com or Reason Foundation. We reserve the right to delete any comment for any reason at any time. Comments may only be edited within 5 minutes of posting. Report abuses.
Please
to post comments
Prior to this lawsuit, I never knew their product was no better than cheap generic alternatives. Now, I would refuse it if offered.
Speaking of Pharma, if we judged CoViD full vaccination by the Electoral College method, it would win 9 states (NM/5, NJ/14, RI/4, HI/4, ME/4, CT/7, VT/3, MA/11, and NH/4) for a total of 56 votes (about 10% of 538), making it rival Alf Landon's 8% share of votes: Goldwater, Carter, McClellan, Pickney, McGovern, and Mondale would garner more votes.
[The post looked so lonely without irrelevant comments.]
If over 70, get it. Under 40, it's totally optional and OK if you do not. 41 to 69, no idea if you should.
This is the flu turned into a catastrophic assault on our nation by the tech billionaires to get rid of Trump and to enrich themselves by $1.7 trillion. They did a great job.
The lawyer profession can help this country by seizing the assets of these pirates in civil forfeiture for the millions of crimes committed on their platforms.
Perhaps the firm has recognized the serious risk of sanctions if it proceeds with requesting a preliminary injunction.
Hmm.
https://www.justice.gov/usao-nj/pr/pharmaceutical-company-agrees-pay-35-million-resolve-allegations-violating-false-claims
Replying to my own comment, but hmm again. Scroll down to comments.
https://retractionwatch.com/2021/04/15/pharma-company-demands-retraction-damages-in-lawsuit-against-journal/
The comment by Stephen Shaffer in the link seems particularly telling. The comment lists a series of trials where Pacira repeatedly tried to show that their product was superior to the old generic version and failed. He says they got their approval by launching a new set of trials showing it superior to placebo.
In that’s the case, then the gist of what the academics are saying, that it’s more expensive than the generic, doesn’t work better, and isn’t worth the extemra money, would seem unassailable.
Question for Professor Volokh:
Are you, other legal academics, university organizations, First Amendment defense nonprofits, or similar folks filing any amicus curiae briefs in this case?